Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 10,624 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 10,624 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total value of $184,007.68. Following the completion of the sale, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $1,238,813. This represents a 12.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $17.60 on Wednesday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $2.32 billion, a P/E ratio of -11.50 and a beta of 1.52. Centessa Pharmaceuticals plc has a 1-year low of $6.65 and a 1-year high of $18.97. The firm has a 50-day moving average of $16.56 and a 200-day moving average of $13.46.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets upped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Jefferies Financial Group upped their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company. Finally, Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares in the last quarter. Quarry LP increased its position in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after buying an additional 3,108 shares during the period. Sandia Investment Management LP bought a new position in Centessa Pharmaceuticals in the second quarter worth about $90,000. Finally, Fred Alger Management LLC purchased a new stake in Centessa Pharmaceuticals in the second quarter worth about $99,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.